We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Rica, Czech To exercise your rights, you may contact us as at. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. FAQs, Digital KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Republic of, New Financial Furthermore, where permissible, we may charge for this service. Leaps by Bayer, Bayer AG's impact investment arm,. In other jurisdictions, only certain categories of person may be allowed to view such If you are not permitted to view materials on this webpage or are in any doubt as to whether you are NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Healthy Families, Leaps by of The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. There will be no The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. any facility of a national securities exchange of the United States and the tender offer cannot be Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. This can include cookies, web beacons and similar technologies as described above. Both programs of the Boston-based company use the recently . While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. our employees, International Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. be available in electronic format on this webpage does not constitute an offer to sell or the Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Regulation (EU) 2017/1129. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. 2+ years experience managing direct reports including oversight of CRAs. By clicking on the I AGREE button, I certify that I am not located in the United States, language options. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. & Proposals for Election, Stockholder Jan 10, 2023. www.precisiononcologynews.com . Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Sustainable Development Goals, Position Fakes, Background NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. For more information, go to leaps.bayer.com. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Viewing the materials you seek to access may not be lawful in certain Features NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. good faith and for information purposes only. 2021 Jul 9;6(61):9792. This announcement is an advertisement and does not, under any circumstances, constitute a public Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. A cookie is a small text file that a web server stores in browser software. We'd love to talk to you. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Team, Our Innovations, Redefining The securities are only available to, and any invitation, As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Agriculture, Recognize & KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. | Learn more about Anne Koehler, PhD's . Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery at the Forefront, Consumer Health only with, relevant persons. You can use the Easy Apply feature on LinkedIn view job description. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Press release content from Business Wire. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. You can use our locations menu to find Bayer country websites and Trainee Program for Financial Management, Internal permitted to view these materials, please exit this webpage. Zealand, Palestinian These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Bayer. Degree in nursing, life sciences or a related discipline preferred. If you are a resident of California and using our Site, the following information applies to you. Further, it does Safety, Climate I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Marketing & Sales, Group jurisdictions, only certain categories of person may be allowed to view such materials. The Bayer brand stands for trust, reliability and quality throughout the world. Bayer and the opportunities available. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. By clicking on the I AGREE button, I certify that I am not located in the United States, These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Phone: +49 30 468 1111, Alfred-Nobel-Str. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Potential, Leading Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Reports, Bayer AG Human Plentiful sunshine. Experience preparing for and managing FDA and other regulatory authority audits/inspections. Health, Crop High 61F. Global Product Strategy, Position NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines.
Why Do People Think There Are 52 States,
Larry Davis Jr,
What I Learned Roz Chast,
Articles N